Strategic Decision-Making in Pharma: The Initial Bioequivalence Risk Assessment Tool Project with Sandoz

Axiologo, in collaboration with Sandoz, has developed the Initial Bioequivalence Risk Assessment Tool, a pioneering project aimed at revolutionizing the preliminary stages of pharmaceutical research and development. This cutting-edge initiative seeks to equip decision-makers with the ability to evaluate the risk and potential profitability of drug development projects before the initiation of sample batches, thereby refining the selection process for future drug development endeavors.

Project Overview

Key Goals:

  • Risk Assessment: To assess the potential risks associated with the R&D process for selected drugs/APIs, including evaluating Biopharmaceutics Classification System (BCS) classifications and other critical factors, prior to experimental commencement.
  • Strategic Development: Enable strategic decision-making in the early stages of drug development, allowing Sandoz to prioritize projects based on a comprehensive understanding of risk and profitability.

Technologies Deployed:

  • Python Modeling: Utilized for its robust data analysis and predictive modeling capabilities, enabling accurate risk assessments.
  • Dash Frontend: Provided an intuitive interface for interacting with the risk assessment models, with potential for integration into existing systems or development in preferred technologies like React, PowerBI, or Excel.


  • Informed Decision-Making: The project has significantly improved the decision-making process within Sandoz, offering enhanced insight and transparency into the potential risks and rewards of drug development projects.
  • Strategic Insight: By providing a clear evaluation of risks before entering the R&D phase, the tool allows for a more strategic approach to drug development, prioritizing projects with the optimal balance of risk and profitability.

The Path Forward

The development and implementation of the Initial Bioequivalence Risk Assessment Tool mark a significant advancement in strategic planning for pharmaceutical R&D. This tool underscores the importance of early-stage risk assessment. Moving forward, the insights garnered from this project will continue to influence Sandoz’s approach to drug development, setting a new standard for efficiency and strategic foresight in the pharmaceutical industry.

This initiative demonstrates the transformative potential of AI and data analytics in enhancing the pharmaceutical drug development process, ensuring that future projects are not only scientifically viable but also strategically aligned with corporate objectives and market demands.